Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Trial details
- Registry ID
- NCT07520006
- Phase
- Phase 1, Phase 2
The FDA approved obinutuzumab on 1 Nov 2013.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesNCT07520006 | NRIX | Phase 1, Phase 2 | Recruiting | 2033-05Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2013-11-01Day | obinutuzumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125486", "applicant_as_listed_by_fda": "GENENTECH", "brand_names": ["GAZYVA"], "active_ingredients": ["OBINUTUZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20131101", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 26 Oct 2026 · Evidence last checked: 26 Oct 2026 |